1
|
Sequist L, Gerber D, Fidias P, Shaw A, Temel J, Heist R, Gainor J, Fulton L, Kennedy E, Muzikansky A, Engelma J. Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.08.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
2
|
Piotrowska Z, Niederst M, Mino-Kenudson M, Morales-Oyarvide V, Fulton L, Lockerman E, Howe E, Gainor J, Fidias P, Heist R, Shaw A, Engelman J, Sequist L. Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.08.032] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22:2616-2624. [PMID: 22071650 DOI: 10.1093/annonc/mdr489] [Citation(s) in RCA: 297] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Personalizing non-small-cell lung cancer (NSCLC) therapy toward oncogene addicted pathway inhibition is effective. Hence, the ability to determine a more comprehensive genotype for each case is becoming essential to optimal cancer care. METHODS We developed a multiplexed PCR-based assay (SNaPshot) to simultaneously identify >50 mutations in several key NSCLC genes. SNaPshot and FISH for ALK translocations were integrated into routine practice as Clinical Laboratory Improvement Amendments-certified tests. Here, we present analyses of the first 589 patients referred for genotyping. RESULTS Pathologic prescreening identified 552 (95%) tumors with sufficient tissue for SNaPshot; 51% had ≥1 mutation identified, most commonly in KRAS (24%), EGFR (13%), PIK3CA (4%) and translocations involving ALK (5%). Unanticipated mutations were observed at lower frequencies in IDH and β-catenin. We observed several associations between genotypes and clinical characteristics, including increased PIK3CA mutations in squamous cell cancers. Genotyping distinguished multiple primary cancers from metastatic disease and steered 78 (22%) of the 353 patients with advanced disease toward a genotype-directed targeted therapy. CONCLUSIONS Broad genotyping can be efficiently incorporated into an NSCLC clinic and has great utility in influencing treatment decisions and directing patients toward relevant clinical trials. As more targeted therapies are developed, such multiplexed molecular testing will become a standard part of practice.
Collapse
Affiliation(s)
- L V Sequist
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston.
| | - R S Heist
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston
| | - A T Shaw
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston
| | - P Fidias
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston
| | - R Rosovsky
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston; The Mass General/North Shore Cancer Center, Danvers
| | - J S Temel
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston
| | - I T Lennes
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston
| | - S Digumarthy
- Harvard Medical School, Boston; Department of Radiology
| | | | - E Bast
- Massachusetts General Hospital Cancer Center, Boston
| | - S Tammireddy
- Massachusetts General Hospital Cancer Center, Boston
| | - L Morrissey
- Massachusetts General Hospital Cancer Center, Boston
| | - A Muzikansky
- Harvard Medical School, Boston; Department of Biostatistics
| | - S B Goldberg
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston
| | - J Gainor
- Harvard Medical School, Boston; Department of Medicine
| | - C L Channick
- Harvard Medical School, Boston; Division of Pulmonary and Critical Care Medicine
| | - J C Wain
- Harvard Medical School, Boston; Division of Thoracic Surgery
| | - H Gaissert
- Harvard Medical School, Boston; Division of Thoracic Surgery
| | - D M Donahue
- Harvard Medical School, Boston; Division of Thoracic Surgery
| | - A Muniappan
- Harvard Medical School, Boston; Division of Thoracic Surgery
| | - C Wright
- Harvard Medical School, Boston; Division of Thoracic Surgery
| | - H Willers
- Harvard Medical School, Boston; Department of Radiation Oncology, Massachusetts General Hospital, Boston
| | - D J Mathisen
- Harvard Medical School, Boston; Division of Thoracic Surgery
| | - N C Choi
- Harvard Medical School, Boston; Department of Radiation Oncology, Massachusetts General Hospital, Boston
| | - J Baselga
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston
| | - T J Lynch
- Yale University School of Medicine and Yale Cancer Center, New Haven
| | - L W Ellisen
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston
| | - M Mino-Kenudson
- Harvard Medical School, Boston; Department of Pathology, Massachusetts General Hospital, Boston, USA
| | - M Lanuti
- Harvard Medical School, Boston; Division of Thoracic Surgery
| | - D R Borger
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston
| | - A J Iafrate
- Harvard Medical School, Boston; Department of Pathology, Massachusetts General Hospital, Boston, USA
| | - J A Engelman
- Massachusetts General Hospital Cancer Center, Boston; Harvard Medical School, Boston
| | - D Dias-Santagata
- Harvard Medical School, Boston; Department of Pathology, Massachusetts General Hospital, Boston, USA
| |
Collapse
|
4
|
Sequist LV, Heist RS, Shaw AT, Fidias P, Temel JS, Lennes IT, Bast E, Waltman BA, Lanuti M, Muzikansky A, Mino-Kenudson M, Iafrate AJ, Borger DR, Dias-Santagata D, Engelman JA. SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7518] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Heist RS, Duda GD, Sahani D, Ancukiewicz M, Fidias P, Sequist LV, Shaw AT, Temel JS, Lennes IT, Neal JW, Pennell NA, Lynch TJ, Engelman JA, Jain RK. Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol 2011; 22:1367-1373. [PMID: 21217058 DOI: 10.1093/annonc/mdq604] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of esophageal and gastric carcinomas. Although previous studies have examined tyrosine kinase inhibitors of EGFR, there remains limited data regarding the role of EGFR-directed monoclonal antibody therapy in these malignancies. We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma. PATIENTS AND METHODS Thirty-five patients with previously treated metastatic esophageal or gastric adenocarcinoma were treated with weekly cetuximab, at an initial dose of 400 mg/m(2) followed by weekly infusions at 250 mg/m(2). Patients were followed for toxicity, treatment response, and survival. RESULTS Treatment with cetuximab was well tolerated; no patients were taken off study due to drug-related adverse events. One (3%) partial treatment response was noted. Two (6%) patients had stable disease after 2 months of treatment. Median progression-free survival and overall survival were 1.6 and 3.1 months, respectively. CONCLUSION Although well tolerated, cetuximab administered as a single agent had minimal clinical activity in patients with metastatic esophageal and gastric adenocarcinoma. Ongoing studies of EGFR inhibitors in combination with other agents may define a role for these agents in the treatment of esophageal and gastric cancer.
Collapse
Affiliation(s)
- J A Chan
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital, Boston; Department of Hematology/Oncology, Harvard Medical School.
| | - L S Blaszkowsky
- Department of Hematology/Oncology, Harvard Medical School; Division of Hematology/Oncology, Department of Medicine
| | - P C Enzinger
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital, Boston; Department of Hematology/Oncology, Harvard Medical School
| | - D P Ryan
- Department of Hematology/Oncology, Harvard Medical School; Division of Hematology/Oncology, Department of Medicine
| | - T A Abrams
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital, Boston; Department of Hematology/Oncology, Harvard Medical School
| | - A X Zhu
- Department of Hematology/Oncology, Harvard Medical School; Division of Hematology/Oncology, Department of Medicine
| | - J S Temel
- Department of Hematology/Oncology, Harvard Medical School; Division of Hematology/Oncology, Department of Medicine
| | - D Schrag
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital, Boston; Department of Hematology/Oncology, Harvard Medical School
| | - P Bhargava
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital, Boston; Department of Hematology/Oncology, Harvard Medical School
| | - J A Meyerhardt
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital, Boston; Department of Hematology/Oncology, Harvard Medical School
| | - B M Wolpin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital, Boston; Department of Hematology/Oncology, Harvard Medical School
| | - P Fidias
- Department of Hematology/Oncology, Harvard Medical School; Division of Hematology/Oncology, Department of Medicine
| | - H Zheng
- Department of Hematology/Oncology, Harvard Medical School; Biostatistics Center, Massachusetts General Hospital, Boston, USA
| | - S Florio
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - E Regan
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - C S Fuchs
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital, Boston; Department of Hematology/Oncology, Harvard Medical School
| |
Collapse
|
7
|
Choi N, Chun T, Niemierko A, Ancukiewicz M, Fidias P, Kradin R, Mathisen D, Lynch T, Fischman A. FDG Uptake Quantified with FDG PET 10-12 Days after Radiotherapy or Chemoradiotherapy in Lung Cancer is Molecular-Biomarker Capable for Predicting Therapy Outcome and Identifying Patients in Need for Timely Salvage Therapy. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Fidias P, Ciuleanu TA, Gladkov O, Manikhas GM, Bondarenko IN, Pluzanska A, Ramlau R, Lynch TJ. A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.18_suppl.lba7007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA7007 Background: NOV-002 is a formulation of disodium glutathione disulfide (GSSG). GSSG is a naturally occurring substance that functions as a component of the glutathione (GSH) pathway, vital to the regulation of the intracellular redox state. A key function of the GSH/GSSG redox couple is to dynamically regulate protein functions, including cell signaling pathways, through the reversible formation of mixed disulfides between protein cysteines and GSH (S-glutathionylation). Based on positive results from a randomized, phase I/II study of carboplatin and paclitaxel (CP) with or without NOV-002, as well as positive results from 2 ex-U.S. phase II studies with cisplatin-based chemotherapy, an international phase III randomized trial was launched. Methods: Patients with advanced NSCLC (stages wet IIIB and IV, inclusive of all histological subtypes) were eligible if they had a PS of 0-1 and adequate end-organ function. Patients with CNS metastases were excluded. Eligible patients were randomized to C (AUC 6), P (200 mg/m2), and NOV-002 (Group A) or C and P alone (Group B). NOV-002 was administered as two-60 mg IV boluses on day -1 of cycle 1 and as one IV bolus on day 1 of each cycle, followed by daily 60-mg subcutaneous injections. A total of 725 events were required to detect a difference in overall survival (OS) from 10.0 to 12.5 months with 85% power and a two-sided significance level of 0.05. No interim analysis was performed. Results: From 11/06 until 9/09, 903 patients were randomized, with target enrollment reached in March 2008. Patient characteristics for Groups A and B were as follows: stage IV (91.5/90.8%), PS 1 (76.6/72.6%), male (69.9/72.4%), never smoker (22.3/19.1%) median age (59.6/59.5), and histology (adenocarcinoma [40.0/36.8%] squamous [41.2/40.8%]). The median overall survival for Groups A and B was 10.2/10.8 months (p = 0.375), median progression-free survival was 5.3/5.6 months, objective response rate was 26.6/26.0% and 54/53% of patients completed at least six cycles of chemotherapy. Major toxicities for Groups A and B included grade 3/4 neutropenia (29.7/26.3%), febrile neutropenia (2.2/1.8%), grade 3/4 thrombocytopenia (3.8/2.9%), and grade 3/4 neuropathy (2.9/2.4%). Adverse events resulting in death in Groups A and B were reported in 5.6 and 3.1%, respectively. Conclusions: The addition of NOV-002 to CP does not improve overall survival in patients with advanced NSCLC. NOV002 does not appear to add to the overall toxicity of chemotherapy. [Table: see text]
Collapse
Affiliation(s)
- P. Fidias
- Massachusetts General Hospital Cancer Center, Boston, MA; Institute of Oncology Cluj-Napoca, Cluj-Napoca, Romania; Regional Oncology Center, Chelyabinsk, Russia; City Clinical Oncology Center, St. Petersburg, Russia; City Clinical Hospital, Dnepropetrovsk, Ukraine; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
| | - T. A. Ciuleanu
- Massachusetts General Hospital Cancer Center, Boston, MA; Institute of Oncology Cluj-Napoca, Cluj-Napoca, Romania; Regional Oncology Center, Chelyabinsk, Russia; City Clinical Oncology Center, St. Petersburg, Russia; City Clinical Hospital, Dnepropetrovsk, Ukraine; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
| | - O. Gladkov
- Massachusetts General Hospital Cancer Center, Boston, MA; Institute of Oncology Cluj-Napoca, Cluj-Napoca, Romania; Regional Oncology Center, Chelyabinsk, Russia; City Clinical Oncology Center, St. Petersburg, Russia; City Clinical Hospital, Dnepropetrovsk, Ukraine; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
| | - G. M. Manikhas
- Massachusetts General Hospital Cancer Center, Boston, MA; Institute of Oncology Cluj-Napoca, Cluj-Napoca, Romania; Regional Oncology Center, Chelyabinsk, Russia; City Clinical Oncology Center, St. Petersburg, Russia; City Clinical Hospital, Dnepropetrovsk, Ukraine; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
| | - I. N. Bondarenko
- Massachusetts General Hospital Cancer Center, Boston, MA; Institute of Oncology Cluj-Napoca, Cluj-Napoca, Romania; Regional Oncology Center, Chelyabinsk, Russia; City Clinical Oncology Center, St. Petersburg, Russia; City Clinical Hospital, Dnepropetrovsk, Ukraine; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
| | - A. Pluzanska
- Massachusetts General Hospital Cancer Center, Boston, MA; Institute of Oncology Cluj-Napoca, Cluj-Napoca, Romania; Regional Oncology Center, Chelyabinsk, Russia; City Clinical Oncology Center, St. Petersburg, Russia; City Clinical Hospital, Dnepropetrovsk, Ukraine; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
| | - R. Ramlau
- Massachusetts General Hospital Cancer Center, Boston, MA; Institute of Oncology Cluj-Napoca, Cluj-Napoca, Romania; Regional Oncology Center, Chelyabinsk, Russia; City Clinical Oncology Center, St. Petersburg, Russia; City Clinical Hospital, Dnepropetrovsk, Ukraine; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
| | - T. J. Lynch
- Massachusetts General Hospital Cancer Center, Boston, MA; Institute of Oncology Cluj-Napoca, Cluj-Napoca, Romania; Regional Oncology Center, Chelyabinsk, Russia; City Clinical Oncology Center, St. Petersburg, Russia; City Clinical Hospital, Dnepropetrovsk, Ukraine; Klinika Chemioterapii Nowotworow AM, Lodz, Poland; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT
| |
Collapse
|
9
|
Waltman BA, Dias-Santagata D, Cosper AK, Mino-Kenudson M, Borger DR, Fidias P, Shaw AT, Iafrate AJ, Engelman JA, Sequist LV. SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7554] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, Meyerhardt JA, Blaszkowsky LS, Zhu AX, Fidias P, Vincitore MM, Mayer RJ, Fuchs CS. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol 2009; 20:475-80. [PMID: 19139178 DOI: 10.1093/annonc/mdn658] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Recent studies have examined the addition of docetaxel to fluorouracil and cisplatin in advanced esophagogastric cancer. PATIENTS AND METHODS We carried out a phase I dose-escalation study of weekly docetaxel, cisplatin, and irinotecan (TPC), given on days 1 and 8 every 3 weeks, in patients with chemonaive solid tumors. Subsequently, we completed a multiinstitutional phase II study of TPC in patients with previously untreated, metastatic esophagogastric cancer. RESULTS Thirty-nine patients were enrolled in the phase I trial; a weekly schedule of TPC was well tolerated. On that basis, docetaxel 30 mg/m(2), cisplatin 25 mg/m(2), and irinotecan 65 mg/m(2) were selected for the phase II trial, where in the first 18 patients irinotecan 65 mg/m(2) caused too much diarrhea and was reduced to 50 mg/m(2). Among 56 eligible patients with previously untreated, metastatic esophagogastric cancer enrolled in the phase II trial, three complete and 27 partial responses were observed (overall response rate=54%), and 15 patients (30%) had stable disease. Median progression-free survival was 7.1 months, and median survival was 11.9 months. At the final irinotecan dose of 50 mg/m(2), grade 3 or higher toxicity included diarrhea (26%), neutropenia (21%), nausea (18%), fatigue (16%), anorexia (13%), and thrombosis/embolism (13%). CONCLUSIONS Weekly TPC is an active and well-tolerated regimen for patients with esophagogastric cancer.
Collapse
Affiliation(s)
- P C Enzinger
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Enzinger PC, Ryan DP, Regan EM, Lehman N, Abrams TA, Hezel AF, Fidias P, Sequist LV, Blaszkowsky LS, Fuchs CS. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4552] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Choi N, Chun T, Ancukiewicz M, Niemierko A, Fidias P, Fischman A. FDG Uptake at Sequential Intervals After Radiotherapy (RT) or RT of Chemo-Radiotherapy (CT+RT) and its Predictive Value for Tumor Control Probability (TCP) of Metastatic Lung Cancer in Regional Lymph Nodes. Int J Radiat Oncol Biol Phys 2007. [DOI: 10.1016/j.ijrobp.2007.07.1705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Burris H, Krug L, Shapiro G, Fidias P, Crawford J, Reiman T, Michelson G, Young D, Adelman D, Ettinger D. 6547 POSTER SNS-595: Preliminary results of 2 phase 2 second line studies in lung cancer. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71375-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
14
|
Heist RS, Fidias P, Huberman M, Temel J, Sequist L, Lynch TJ. Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7700] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7700 Background: Single agent chemotherapy is standard for second and third line therapy of NSCLC. Combination therapy has to date not proven to be superior to single agents –often adding additional toxicity without any additional efficacy. We investigated whether the combination of oxaliplatin, pemetrexed, and bevacizumab was an active and tolerable regimen in the pre-treated advanced NSCLC setting. Methods: In this two-stage phase II trial, patients received pemetrexed (500 mg/m2), oxaliplatin (120 mg/m2), and bevacizumab (15 mg/kg) on day 1 of every 21 day cycle, for a total of 6 cycles or until disease progression. Eligibility criteria included PS 0–1, non-squamous histology, and at least one prior chemotherapy regimen. Patients with treated brain metastases were allowed on this trial. The primary endpoint was response rate, with secondary endpoints of TTP, PFS, and OS. Results: 36 patients were enrolled on this study. Patient characteristics for 32 for which data is available were: 16 (50%) women, 16 (50%) men, 26 (81%) adenocarcinoma, 6 (19%) large cell or NSCLC, 6 (19%) treated brain metastases. Of the 31 patients evaluable for tumor response, 0 had CR, 8 (25%) had PR, 14 (44%) had SD, and 9 (28%) had PD. One patient experienced Grade V hemoptysis after cycle 2 before restaging. Nine patients experienced a Grade III/IV serious adverse event. These Grade III/IV toxicities included: cardiac ischemia (1), sensory neuropathy (1), dyspnea (1), anemia (1), constipation (1), fatigue (1), colitis (1), face pain (1), hyperglycemia (1), elevated ALT (1). Among the 6 patients with treated brain metastases, there was 1 PR, 2 SD, 2 PD, and one patient with Grade V hemoptysis whose response could not be assessed; there were no brain hemorrhage events. Data for PFS and OS are preliminary; estimated median PFS is 5.8 months (95% CI 3.8 - 8.9 mo), and estimated OS is 10.9 mo (95% CI 6.4 - 20 mo). Updated data will be presented at the time of the meeting. Conclusions: This data suggests that the combination of pemetrexed, oxaliplatin, and bevacizumab is tolerable and has a promising response rate. Updated data will be presented at the meeting. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. S. Heist
- Massachusetts General Hosp, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA
| | - P. Fidias
- Massachusetts General Hosp, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA
| | - M. Huberman
- Massachusetts General Hosp, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA
| | - J. Temel
- Massachusetts General Hosp, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA
| | - L. Sequist
- Massachusetts General Hosp, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA
| | - T. J. Lynch
- Massachusetts General Hosp, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA
| |
Collapse
|
15
|
Fidias P, Dakhil S, Lyss A, Loesch D, Waterhouse D, Cunneen J, Chen R, Treat J, Obasaju C, Schiller J. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: Updated report with survival. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.lba7516] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA7516 Background: Gemcitabine (G) plus carboplatin (C) therapy is active in patients with advanced non-small-cell lung cancer (NSCLC). For nonprogressing patients, optimal timing of second-line therapy with a non-cross-resistant agent is unclear. This Phase III, randomized trial assessed the efficacy and safety of docetaxel (D) administered either immediately after GC induction therapy or upon disease progression (PD). Methods: Patients having either Stage IIIB with pleural effusion or Stage IV NSCLC were enrolled. Prior chemotherapy for NSCLC was not permitted. For GC induction, G 1000 mg/m2 was administered on Days 1, 8 followed by C AUC 5 on Day 1. After four 21-day cycles, nonprogressors were randomized to either the immediate D group (D 75 mg/m2 administered on Day 1 every 21 days, for a maximum of 6 cycles) or the delayed D group (patients given best supportive care after randomization and the same D regimen after first evidence of PD) treatment arms. Primary endpoint was overall survival (OS). Additional analyses included response rates, toxicity and progression-free survival (PFS). Results: Results are summarized in the table below. OS was not statistically different (p=0.071) between the two D arms. However, 31 patients (20.1%) in the delayed D arm and 38 patients (24.8%) in the immediate D arm were censored for OS analysis. PFS analysis (from randomization to first evidence of PD or death) showed a statistically significant (p=<0.0001) improvement in the immediate D arm. D given to NSCLS patients immediately after GC induction did not increase toxicity. Conclusions: Comparison of PFS for each D arm suggests a possible clinical benefit for immediate D therapy. However, even though OS trended in favor of immediate D therapy, the OS result did not reach statistical significance. The implications of these results will be discussed. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- P. Fidias
- Massachusetts General Hosp, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - S. Dakhil
- Massachusetts General Hosp, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - A. Lyss
- Massachusetts General Hosp, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - D. Loesch
- Massachusetts General Hosp, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - D. Waterhouse
- Massachusetts General Hosp, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - J. Cunneen
- Massachusetts General Hosp, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - R. Chen
- Massachusetts General Hosp, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - J. Treat
- Massachusetts General Hosp, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - C. Obasaju
- Massachusetts General Hosp, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - J. Schiller
- Massachusetts General Hosp, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| |
Collapse
|
16
|
McCann J, Fossella FV, Villalona-Calero MA, Tolcher AW, Fidias P, Raju R, Zildjian S, Guild R, Fram R. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18084] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18084 Background: HuN901-DM1, a humanized antibody-maytansinoid immunoconjugagte, binds to CD56 which is expressed in almost all cases of SCLC as well as in other small cell carcinomas (SCC), neuroendocrine carcinomas, and multiple myeloma. The immunoconjugate binds to its target antigen, is internalized, then releases DM1. Methods: Patients with relapsed SCLC and CD56- positive SCC of other sites are treated with huN901-DM1 given as an intravenous infusion at 60 mg/m2/week for four consecutive weeks every six weeks. The study consists of two stages. Fourteen patients were initially enrolled. The occurrence of an objective response among the initial 14 patients prompted expansion to a total of 35 evaluable patients. Clinical response is evaluated by RECIST criteria. Results: To date, thirty patients have been treated in the study. Four patients experienced drug related serious adverse events (SAEs). Three patients had severe headache after the initial infusion of study drug. Symptoms markedly improved after 24 hours and then completely resolved. Severe headaches did not occur in subsequent patients who were pre-medicated with steroids prior to all infusions. A patient with a history of diabetic neuropathy and prior cisplatin treatment had grade 4 hyperesthesia. There was no evidence of clinically significant myelosuppression. HuN901-DM1 generally was well tolerated and no serious infusion reactions occurred. Preliminary pharmacokinetic (PK) data reveal no prolongation of terminal half-life of the immunoconjugate when PK parameters are compared from the first and fourth dose of cycle 1. Further, there was no evidence of antibody formation to the antibody component (HAHA) or drug component (HADA) of huN901-DM1. One patient (pt) with relapsed, SCLC had an objective partial response lasting 18 weeks and a pt with cervical SCC had an unconfirmed partial response. Stable disease was observed in five patients and lasted about 6 (3 pts), 12 (1 pt), and 18 weeks (1 pt). Conclusions: The study provides evidence of clinical activity and safety of huN901-DM1. Pre-medication with steroids appears effective in preventing severe headaches. Enrollment of additional patients to the study is planned. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. McCann
- Baystate Medical Center, Springfield, MA; M.D. Anderson Cancer Center, Houston, TX; Ohio State University, Columbus, OH; Institute of Drug Development, San Antonio, TX; Massachusetts General Hospital, Boston, MA; Greater Dayton Cancer Center, Dayton, OH; ImmunoGen, Inc., Boston, MA
| | - F. V. Fossella
- Baystate Medical Center, Springfield, MA; M.D. Anderson Cancer Center, Houston, TX; Ohio State University, Columbus, OH; Institute of Drug Development, San Antonio, TX; Massachusetts General Hospital, Boston, MA; Greater Dayton Cancer Center, Dayton, OH; ImmunoGen, Inc., Boston, MA
| | - M. A. Villalona-Calero
- Baystate Medical Center, Springfield, MA; M.D. Anderson Cancer Center, Houston, TX; Ohio State University, Columbus, OH; Institute of Drug Development, San Antonio, TX; Massachusetts General Hospital, Boston, MA; Greater Dayton Cancer Center, Dayton, OH; ImmunoGen, Inc., Boston, MA
| | - A. W. Tolcher
- Baystate Medical Center, Springfield, MA; M.D. Anderson Cancer Center, Houston, TX; Ohio State University, Columbus, OH; Institute of Drug Development, San Antonio, TX; Massachusetts General Hospital, Boston, MA; Greater Dayton Cancer Center, Dayton, OH; ImmunoGen, Inc., Boston, MA
| | - P. Fidias
- Baystate Medical Center, Springfield, MA; M.D. Anderson Cancer Center, Houston, TX; Ohio State University, Columbus, OH; Institute of Drug Development, San Antonio, TX; Massachusetts General Hospital, Boston, MA; Greater Dayton Cancer Center, Dayton, OH; ImmunoGen, Inc., Boston, MA
| | - R. Raju
- Baystate Medical Center, Springfield, MA; M.D. Anderson Cancer Center, Houston, TX; Ohio State University, Columbus, OH; Institute of Drug Development, San Antonio, TX; Massachusetts General Hospital, Boston, MA; Greater Dayton Cancer Center, Dayton, OH; ImmunoGen, Inc., Boston, MA
| | - S. Zildjian
- Baystate Medical Center, Springfield, MA; M.D. Anderson Cancer Center, Houston, TX; Ohio State University, Columbus, OH; Institute of Drug Development, San Antonio, TX; Massachusetts General Hospital, Boston, MA; Greater Dayton Cancer Center, Dayton, OH; ImmunoGen, Inc., Boston, MA
| | - R. Guild
- Baystate Medical Center, Springfield, MA; M.D. Anderson Cancer Center, Houston, TX; Ohio State University, Columbus, OH; Institute of Drug Development, San Antonio, TX; Massachusetts General Hospital, Boston, MA; Greater Dayton Cancer Center, Dayton, OH; ImmunoGen, Inc., Boston, MA
| | - R. Fram
- Baystate Medical Center, Springfield, MA; M.D. Anderson Cancer Center, Houston, TX; Ohio State University, Columbus, OH; Institute of Drug Development, San Antonio, TX; Massachusetts General Hospital, Boston, MA; Greater Dayton Cancer Center, Dayton, OH; ImmunoGen, Inc., Boston, MA
| |
Collapse
|
17
|
Oxnard GR, Fidias P, Sequist LV. Treatment patterns of very elderly patients with non-small cell lung cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18110 Background: Among patients with non-small cell lung cancer (NSCLC), patients aged 80 or older, termed the ‘very elderly‘, have inferior survival. Treatment patterns within this patient population are poorly described. Methods: A retrospective chart review was performed of 111 outpatients with NSCLC presenting at age 80 or older to an academic referral center over 5.3 years. Based upon available literature regarding elderly patients with NSCLC, a guideline recommended therapy (GRT) was determined for each tumor stage. Each patient’s treatment regimen was evaluated for consistency with the GRT. Particular attention was paid to how patient characteristics and attitudes influenced therapy decisions. Results: Patients characteristics included: median age 82.6 (range 80–92); 50% male; 55% adenocarcinoma, 19% squamous cell; 30% stage I-II, 28% stage III, 39% stage IV; and 59% performance status (PS) 0–1, 25% PS = 2 (PS not available for 15%). 89% of patients received some form of anti-neoplastic therapy and 11% were treated with best supportive care alone. Of 34 patients with localized disease, 53% underwent tumor resection and 38% received definitive radiation. Of 74 patients with stage III or IV disease, 34% received cytotoxic chemotherapy. Radiotherapy (47%) and oral targeted therapy (35%) were the most common treatment modalities overall. 32% of patients received the stage-specific GRT. Multivariable analysis demonstrated that independent predictors for failing to receive GRT included PS = 2 (odds ratio [OR] 17.1, 95% confidence interval [CI] 2.2–135) and age =85 (OR 4.8, 95% CI 1.0–23.4) Of the patients who failed to receive GRT, 19% electively refused GRT that was offered (13% specifically refused chemotherapy), and 76% were not offered GRT (44% due to PS or comorbidities, 32% due to age or unstated reasons). Conclusions: The vast majority of NSCLC patients age 80 or above receive some form of anti-neoplastic therapy, but only one-third of this population receives the stage-specific GRT. The strongest predictor of treatment with GRT is PS 0–1; those with poor PS are 17-fold less likely to receive GRT. A small but clinically significant portion of patients elect against the offered GRT; more data is needed about the attitudes of these patients toward therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - P. Fidias
- Massachusetts General Hospital, Boston, MA
| | | |
Collapse
|
18
|
Chen R, Fidias P, Yock T, Niemierko A, Ancukiewicz M, Hong T, Wolfgang J, Gurubhagavatula S, Choi N. 2490. Int J Radiat Oncol Biol Phys 2006. [DOI: 10.1016/j.ijrobp.2006.07.901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
19
|
Enzinger PC, Yock T, Suh W, Fidias P, Mamon H, Choi N, Lehman N, Lawrence C, Lynch T, Fuchs C. Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4064] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4064 Background: Weekly irinotecan, cisplatin, and concurrent radiation therapy is a well-tolerated, active regimen in locally advanced esophageal cancer. (Ilson. JCO 2003) Cetuximab, an EGFR inhibitor, is a potent radiation sensitizer in head and neck cancer. (Bonner. Proc ASCO 2004) Methods: In this phase II trial, patients (pts) with T2–4N0–1M0–1A esophageal adenocarcinoma (A) or squamous cell carcinoma (S) receive 5040 cGy/28 fractions of radiation therapy (RT) and concurrent weekly cisplatin 30mg/m2 plus irinotecan 65 mg/m2 on weeks 1, 2, 4, and 5, followed by surgery 4–8 weeks after completion of RT. Additionally, pts receive weekly infusions of cetuximab 250 mg during RT, up to one week before surgery, and for 6 months following surgery. Results: Seventeen pts have been entered: male: female = 14:3, median age 54, ECOG PS 0:1 = 6:11, A:S = 17:0, stage IIA:IIB:III:IVA = 6:1:8:2, tumor location-esophagus-mid:lower:gastroesophageal junction = 1:4:12, >10% weight loss-yes:no = 8:9. Of 17 pts entered, 15 pts have proceeded to surgery, 1 pt died from Aspergillus infection resulting in respiratory failure and sepsis, and 1 pt is pending surgery. Of the 15 pts who underwent surgery, 2 (13%) had a complete pathologic response; pathologic stage for other pts: 0 = 1, I = 3, IIA = 3, IIB = 1, III = 4, IV = 1. Grade III/IV toxicity (17 pts) was: diarrhea 9 pts, neutropenia 9 pts, febrile neutropenia 5 pts, anorexia 5 pts, vomiting 4 pts, fatigue 3 pts, mucositis 1 pt. Chemotherapy dose attenuation was required for diarrhea in 5 pts, for neutropenia in 4 pts, and for folliculitis in 1 pt. One patient was removed from study during week 6 for prolonged diarrhea/ dehydration. Due to the 2-step design of the trial, accrual is on hold pending a 3rd required pathologic CR in the first 17 patients. Conclusions: Compared to other trials of irinotecan, cisplatin, radiation therapy, and surgery in similar groups of esophageal cancer patients, early results for this combination with cetuximab suggest a lower complete response rate and higher overall toxicity. Additional data will be available at ASCO. Supported by Bristol-Myers Squibb. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - T. Yock
- Dana-Farber Cancer Institute, Boston, MA
| | - W. Suh
- Dana-Farber Cancer Institute, Boston, MA
| | - P. Fidias
- Dana-Farber Cancer Institute, Boston, MA
| | - H. Mamon
- Dana-Farber Cancer Institute, Boston, MA
| | - N. Choi
- Dana-Farber Cancer Institute, Boston, MA
| | - N. Lehman
- Dana-Farber Cancer Institute, Boston, MA
| | | | - T. Lynch
- Dana-Farber Cancer Institute, Boston, MA
| | - C. Fuchs
- Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
20
|
Jackman DM, Yeap B, Lucca J, Ostler PA, Morse LK, Fidias P, Lynch TJ, Temel J, Johnson BE, Janne PA. Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis of quality of life and symptom response. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7168] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7168 Background: Elderly patients derive survival benefit but significant toxicity from chemotherapy for NSCLC. Erlotinib is associated with reasonable toxicity and has a survival benefit for relapsed patients previously treated with 1–2 chemotherapy regimens. This targeted agent may prove an effective and well-tolerated first-line therapy in elderly patients with advanced disease. Methods: 80 patients (chemo-naïve, age ≥ 70, PS 0–2, stage IIIB/IV NSCLC) were treated with erlotinib 150 mg/d as part of a phase II study. Primary endpoint was survival. QoL was a secondary endpoint, as assessed by LCSS at baseline and q4 weeks until progression. The primary endpoint of QoL analysis was to determine changes from baseline in LCSS score. Patients were eligible for QoL analysis if they completed an LCSS questionnaire at baseline and ≥ 1 other monthly follow-up visit. Each of 9 items was assessed on a 100mm visual analog scale from 0 (best) to 100 (worst); symptom improvement or worsening was based on a change of ≥ 10mm, with decreased scores implying improvement. Score differences between the baseline and best follow-up response of each subscale and total LCSS are assessed by the signed rank test. Results: 64 patients (80%) were eligible for QoL analysis. There was a trend towards improvement in QoL, based on the total LCSS score. Statistically significant improvements in dyspnea, cough, fatigue, and pain were seen, both in terms of median changes from baseline and the proportion of patients improved (Table). No patients were symptomatic for hemoptysis at baseline, so improvement could not be calculated. Conclusions: Erlotinib in elderly patients with advanced NSCLC was associated with encouraging survival (10.9 mo), a trend towards improved QoL, and statistically significant improvements in key symptoms of dyspnea, cough, fatigue, and pain. Mixed effects longitudinal modeling showing changes in LCSS over time will be presented at the conference. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- D. M. Jackman
- Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - B. Yeap
- Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - J. Lucca
- Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - P. A. Ostler
- Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - L. K. Morse
- Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - P. Fidias
- Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - T. J. Lynch
- Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - J. Temel
- Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - B. E. Johnson
- Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - P. A. Janne
- Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
21
|
Temel JS, Jackson VA, Billings A, Prigerson HG, Fidias P, Lynch TJ, Pirl W. The effect of depression on survival in patients with newly diagnosed advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8511] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8511 Background: The impact of emotional distress on cancer-related mortality is unclear. Divergent results in studies are due, in part, from heterogeneous populations in terms of type of cancer, stage of disease, and time of emotional assessment. This study examined the effect of depression and anxiety on a well-defined cohort of patients with newly diagnosed advanced NSCLC. Methods: 46 patients with advanced NSCLC were recruited within eight weeks of diagnosis to participate in a feasibility study of early palliative care. Participants completed the Hospital Anxiety and Depression Scale (HADS) at baseline and were followed for six months. The primary study endpoint was survival at six months. The effects of depression and anxiety were evaluated first by Kaplan-Meier survival analysis and then by Cox regression to control for other variables. Results: Three patients (6%) had stage IIIB with effusions and the remaining 43 (93%) had stage IV disease. The median age of patients was 65.5 years and 28 of the 46 (61%) were women. 34 patients had a PS 1 (74%), 11 (24%) had PS 0 and one (2%) had PS 2. 96% of the patients completed the baseline HADS. 23% met HADS criteria for probable cases of depression (8 or greater) at baseline and 34% met HADS criteria for probable cases of anxiety (8 or greater). Using Kaplan-Meier survival analysis, patients with depression were less likely to have survived at 6 months than non-depressed patients (50% versus 80%, log rank p=0.01). Baseline anxiety did not appear to impact survival. Using Cox proportional hazard regression analyses to control for stage, ECOG performance status, age, and gender, the effect of depression remained significant at p=0.03. Conclusion: Depression in newly diagnosed advanced NSCLC patients was associated with inferior survival in this well-defined patient population. Conversely, anxiety did not appear to be associated with mortality. These findings strengthen the argument that emotional distress influences survival. Larger prospective studies are needed to confirm this conclusion, explore possible mediators, and investigate the effects of treatment for depression. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. S. Temel
- Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA
| | - V. A. Jackson
- Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA
| | - A. Billings
- Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA
| | - H. G. Prigerson
- Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA
| | - P. Fidias
- Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA
| | - T. J. Lynch
- Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA
| | - W. Pirl
- Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
22
|
Sequist LV, Joshi VA, Jänne PA, Fidias P, Muzikansky A, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ. Epidermal growth factor receptor ( EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7177 Background: Somatic mutations in EGFR are associated with response to therapy and prolonged overall survival (OS) of NSCLC pts treated with tyrosine kinase inhibitors (TKI). We began EGFR mutation screening in 2004 with a CLIA certified test. We determined the characteristics of pts tested, EGFR mutations identified, and analyzed response to therapy and OS. Methods: We performed a retrospective cohort study of all NSCLC pts referred for EGFR testing over 1 year. Samples underwent direct sequence analysis of EGFR exons 18–24. We used multivariable logistic regression models to examine associations between mutation and pt characteristics. We used chi-square tests to assess differences in response to therapy by EGFR status and analyzed OS with Cox proportional hazard models, adjusting for age, gender and stage. Results: We screened 269 NSCLC pts for EGFR mutations, including 188 (71%) with unresectable disease and 245 (91%) with adenocarcinoma. Mutations were identified in 62 (23%) pts. 15 samples (6%) yielded insufficient DNA for testing. Mutation was more likely in the 59 never-smokers compared to the 185 ever-smokers [odds ratio (OR) 4.8, 95% confidence interval (CI) 2.5–9.2]. Each added pack-year of smoking history lowered the odds of mutation by 5% (OR 0.95, 95% CI 0.94–0.97). Mutation was more likely in the 12 Asians than in the 212 of all other races (OR 3.7, 95% CI 1.1–12.0). In multivariable analyses, pack-years of smoking remained predictive of mutation (OR 0.96, 95% CI 0.94–0.99). Among 44 pts with unresectable disease undergoing subsequent TKI therapy, the 20 EGFR positive pts had an increased response rate (RR) compared to the 24 EGFR negative pts (60% v. 4%, p < 0.0001). In 27 pts given subsequent chemotherapy, RR was 33% and did not differ by EGFR status. Median follow-up was 9.8 months (mo) (range 0.2–135.8 mo). Among pts with unresectable disease, median OS is estimated to be 22.7 mo in EGFR negative pts and is not reached in EGFR positive pts (HR 0.22, 95% CI 0.80–0.63). Conclusions: Sequencing EGFR for somatic mutations is feasible in routine care of NSCLC pts. 23% of screened pts tested positive, and never smoking was the strongest predictor of mutation. Among patients with unresectable disease, EGFR mutation was associated with an increased RR to TKI therapy and OS. [Table: see text]
Collapse
Affiliation(s)
- L. V. Sequist
- Massachusetts General Hospital, Boston, MA; Laboratory for Molecular Medicine, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA
| | - V. A. Joshi
- Massachusetts General Hospital, Boston, MA; Laboratory for Molecular Medicine, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA
| | - P. A. Jänne
- Massachusetts General Hospital, Boston, MA; Laboratory for Molecular Medicine, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA
| | - P. Fidias
- Massachusetts General Hospital, Boston, MA; Laboratory for Molecular Medicine, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA
| | - A. Muzikansky
- Massachusetts General Hospital, Boston, MA; Laboratory for Molecular Medicine, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA
| | - M. Meyerson
- Massachusetts General Hospital, Boston, MA; Laboratory for Molecular Medicine, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA
| | - D. A. Haber
- Massachusetts General Hospital, Boston, MA; Laboratory for Molecular Medicine, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA
| | - R. Kucherlapati
- Massachusetts General Hospital, Boston, MA; Laboratory for Molecular Medicine, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA
| | - B. E. Johnson
- Massachusetts General Hospital, Boston, MA; Laboratory for Molecular Medicine, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA
| | - T. J. Lynch
- Massachusetts General Hospital, Boston, MA; Laboratory for Molecular Medicine, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
23
|
Fidias P, Dakhil SR, Lyss AP, Loesch DM, Waterhouse D, Cunneen J, Ye Z, Tai F, Obasaju CK, Schiller JH. Updated report of a phase III study of induction therapy with gemcitabine + carboplatin (GC) followed by either delayed vs. immediate second-line therapy with docetaxel (D) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7032 Background: GC is an active regimen in patients with advanced NSCLC. For non-progressors after induction treatment, optimal timing of sequential therapy is unclear. Is it best to sequence immediately to an active non-cross resistant agent or delay the introduction of this agent until time of disease progression (PD)? This trial was designed to answer this question. Methods: Pts with Stage IIIB or IV NSCLC were enrolled. G 1000mg/m2 was administered on day 1,8 followed by C at AUC 5.0 on day 1. After 4 cycles, non-progressers were then randomized to immediate D (75mg/m2 administered on day 1 every 3 wks) or delayed D (pts were observed until first evidence of PD). Conclusions: This study confirms that it is possible to deliver docetaxel immediately following four cycles of GC without significantly increasing toxicity. The response rate of 42.1% and clinical benefit rate (CR+PR+SD) of 88.2% observed in the immediate D arm compares favorably with the rates of 6.1% and 60.6% of the delayed D arm. Additional toxicity and response information will be available at the time of the meeting. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- P. Fidias
- Stanford University, Stanford, CA; Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - S. R. Dakhil
- Stanford University, Stanford, CA; Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - A. P. Lyss
- Stanford University, Stanford, CA; Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - D. M. Loesch
- Stanford University, Stanford, CA; Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - D. Waterhouse
- Stanford University, Stanford, CA; Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - J. Cunneen
- Stanford University, Stanford, CA; Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - Z. Ye
- Stanford University, Stanford, CA; Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - F. Tai
- Stanford University, Stanford, CA; Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - C. K. Obasaju
- Stanford University, Stanford, CA; Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| | - J. H. Schiller
- Stanford University, Stanford, CA; Massachusetts General Hospital, Boston, MA; Penrose Cancer Center of Kansas, Wichita, KS; Missouri Baptist Cancer Center, St. Louis, MO; Central Indiana Cancer Centers, Indianapolis, IN; Oncology Hematology Care, Inc., Cincinnati, OH; Eli Lilly and Company, Indianapolis, IN; University of Wisconsin Hospital, Madison, WI
| |
Collapse
|
24
|
Sequist L, Janne P, Joshi V, Fidias P, Verlander P, Meyerson M, Haber D, Johnson B, Kucherlapati R, Lynch T. PD-156 The Massachusetts General Hospital/Dana-Farber Cancer Institute/Harvard Medical School Partners HealthCare Center for genetics and genomics experience with clinical testing for somatic EGFR mutations in NSCLC patients. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80489-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Belani C, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson K, Ramlau R, Fidias P, Millward M, Fossella F. P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80945-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
26
|
Seguist L, Fidias P, Temel J, Kennedy E, Ostler P, Rabin M, Huberman M, Keck J, Brown G, Lynch T. P-572 Phase I–II trial of TLK286 (telcyta), carboplatin (C), and paclitaxel(P) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81065-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Jackman D, Lucca J, Fidias P, Rabin M, Lynch T, Ostler P, Skarin A, Temel J, Johnson B, Janne P. O-188 Phase II study of the EGFR tyrosine kinase inhibitor erlotinib (Tarceva) in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80322-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Herbst R, Johnson B, Rowbottom J, Fidias P, Lu C, Prager D, Roubec J, Csada E, Dimery I, Heymach J. O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80234-x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Fanucchi M, Fossella F, Fidias P, Natale R, Belt R, Govindan R, Raez L, Schiller J, Kashala O, Kelly K. O-084 Phase 2 study of bortezomib±docetaxel in advanced non-smallcell lung cancer (NSCLC). Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80217-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Temel J, Jackson V, Bilings A, Dahlin C, Fidias P, Buss M, Block S, Ostler P, Kornblith A, Lynch T. P-847 Early palliative care (EPC) in patients with advanced non-smallcell lung cancer (NSCLC) is feasible. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81340-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
31
|
Heymach JV, Johnson BE, Rowbottom JA, Fidias P, Lu C, Prager D, Roubec J, Csada E, Dimery I, Herbst RS. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3023] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. V. Heymach
- Dana-Farber Cancer Inst, Boston, MA; AstraZeneca, Macclesfield, United Kingdom; MA Gen Hosp Cancer Ctr, Boston, MA; Univ of Texas M.D. Anderson Cancer Ctr, Houston, TX; UCLA Medcl Ctr, Los Angeles, CA; Univ Hosp Ostrava-Poruba, Ostrava, Czech Republic; Univ of Szeged, Szeged, Hungary; AstraZeneca, Wilmington, DE
| | - B. E. Johnson
- Dana-Farber Cancer Inst, Boston, MA; AstraZeneca, Macclesfield, United Kingdom; MA Gen Hosp Cancer Ctr, Boston, MA; Univ of Texas M.D. Anderson Cancer Ctr, Houston, TX; UCLA Medcl Ctr, Los Angeles, CA; Univ Hosp Ostrava-Poruba, Ostrava, Czech Republic; Univ of Szeged, Szeged, Hungary; AstraZeneca, Wilmington, DE
| | - J. A. Rowbottom
- Dana-Farber Cancer Inst, Boston, MA; AstraZeneca, Macclesfield, United Kingdom; MA Gen Hosp Cancer Ctr, Boston, MA; Univ of Texas M.D. Anderson Cancer Ctr, Houston, TX; UCLA Medcl Ctr, Los Angeles, CA; Univ Hosp Ostrava-Poruba, Ostrava, Czech Republic; Univ of Szeged, Szeged, Hungary; AstraZeneca, Wilmington, DE
| | - P. Fidias
- Dana-Farber Cancer Inst, Boston, MA; AstraZeneca, Macclesfield, United Kingdom; MA Gen Hosp Cancer Ctr, Boston, MA; Univ of Texas M.D. Anderson Cancer Ctr, Houston, TX; UCLA Medcl Ctr, Los Angeles, CA; Univ Hosp Ostrava-Poruba, Ostrava, Czech Republic; Univ of Szeged, Szeged, Hungary; AstraZeneca, Wilmington, DE
| | - C. Lu
- Dana-Farber Cancer Inst, Boston, MA; AstraZeneca, Macclesfield, United Kingdom; MA Gen Hosp Cancer Ctr, Boston, MA; Univ of Texas M.D. Anderson Cancer Ctr, Houston, TX; UCLA Medcl Ctr, Los Angeles, CA; Univ Hosp Ostrava-Poruba, Ostrava, Czech Republic; Univ of Szeged, Szeged, Hungary; AstraZeneca, Wilmington, DE
| | - D. Prager
- Dana-Farber Cancer Inst, Boston, MA; AstraZeneca, Macclesfield, United Kingdom; MA Gen Hosp Cancer Ctr, Boston, MA; Univ of Texas M.D. Anderson Cancer Ctr, Houston, TX; UCLA Medcl Ctr, Los Angeles, CA; Univ Hosp Ostrava-Poruba, Ostrava, Czech Republic; Univ of Szeged, Szeged, Hungary; AstraZeneca, Wilmington, DE
| | - J. Roubec
- Dana-Farber Cancer Inst, Boston, MA; AstraZeneca, Macclesfield, United Kingdom; MA Gen Hosp Cancer Ctr, Boston, MA; Univ of Texas M.D. Anderson Cancer Ctr, Houston, TX; UCLA Medcl Ctr, Los Angeles, CA; Univ Hosp Ostrava-Poruba, Ostrava, Czech Republic; Univ of Szeged, Szeged, Hungary; AstraZeneca, Wilmington, DE
| | - E. Csada
- Dana-Farber Cancer Inst, Boston, MA; AstraZeneca, Macclesfield, United Kingdom; MA Gen Hosp Cancer Ctr, Boston, MA; Univ of Texas M.D. Anderson Cancer Ctr, Houston, TX; UCLA Medcl Ctr, Los Angeles, CA; Univ Hosp Ostrava-Poruba, Ostrava, Czech Republic; Univ of Szeged, Szeged, Hungary; AstraZeneca, Wilmington, DE
| | - I. Dimery
- Dana-Farber Cancer Inst, Boston, MA; AstraZeneca, Macclesfield, United Kingdom; MA Gen Hosp Cancer Ctr, Boston, MA; Univ of Texas M.D. Anderson Cancer Ctr, Houston, TX; UCLA Medcl Ctr, Los Angeles, CA; Univ Hosp Ostrava-Poruba, Ostrava, Czech Republic; Univ of Szeged, Szeged, Hungary; AstraZeneca, Wilmington, DE
| | - R. S. Herbst
- Dana-Farber Cancer Inst, Boston, MA; AstraZeneca, Macclesfield, United Kingdom; MA Gen Hosp Cancer Ctr, Boston, MA; Univ of Texas M.D. Anderson Cancer Ctr, Houston, TX; UCLA Medcl Ctr, Los Angeles, CA; Univ Hosp Ostrava-Poruba, Ostrava, Czech Republic; Univ of Szeged, Szeged, Hungary; AstraZeneca, Wilmington, DE
| |
Collapse
|
32
|
Fanucchi MP, Fossella F, Fidias P, Natale RB, Belt RJ, Carbone DP, Govindan R, Raez L, Robert F, Schiller J. Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): A phase 2 study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7034] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. P. Fanucchi
- Winship Cancer Institute, Emory Univ, Atlanta, GA; MD Anderson Cancer Ctr, Houston, TX; MA Gen Hosp, Boston, MA; Cedars-Sinai Comprehensive Cancer Ctr, Los Angeles, CA; Kansas City Oncology Hematology Group, Kansas City, MO; Vanderbilt Univ Clin Trials Ctr, Nashville, TN; Washington Univ at St. Louis, St Louis, MO; Sylvester Comprehensive Cancer Ctr, Miami, FL; Univ of Alabama Comprehensive Cancer Ctr, Birmingham, AL; Univ of Wisconsin Comprehensive Cancer Ctr, Madison, WI
| | - F. Fossella
- Winship Cancer Institute, Emory Univ, Atlanta, GA; MD Anderson Cancer Ctr, Houston, TX; MA Gen Hosp, Boston, MA; Cedars-Sinai Comprehensive Cancer Ctr, Los Angeles, CA; Kansas City Oncology Hematology Group, Kansas City, MO; Vanderbilt Univ Clin Trials Ctr, Nashville, TN; Washington Univ at St. Louis, St Louis, MO; Sylvester Comprehensive Cancer Ctr, Miami, FL; Univ of Alabama Comprehensive Cancer Ctr, Birmingham, AL; Univ of Wisconsin Comprehensive Cancer Ctr, Madison, WI
| | - P. Fidias
- Winship Cancer Institute, Emory Univ, Atlanta, GA; MD Anderson Cancer Ctr, Houston, TX; MA Gen Hosp, Boston, MA; Cedars-Sinai Comprehensive Cancer Ctr, Los Angeles, CA; Kansas City Oncology Hematology Group, Kansas City, MO; Vanderbilt Univ Clin Trials Ctr, Nashville, TN; Washington Univ at St. Louis, St Louis, MO; Sylvester Comprehensive Cancer Ctr, Miami, FL; Univ of Alabama Comprehensive Cancer Ctr, Birmingham, AL; Univ of Wisconsin Comprehensive Cancer Ctr, Madison, WI
| | - R. B. Natale
- Winship Cancer Institute, Emory Univ, Atlanta, GA; MD Anderson Cancer Ctr, Houston, TX; MA Gen Hosp, Boston, MA; Cedars-Sinai Comprehensive Cancer Ctr, Los Angeles, CA; Kansas City Oncology Hematology Group, Kansas City, MO; Vanderbilt Univ Clin Trials Ctr, Nashville, TN; Washington Univ at St. Louis, St Louis, MO; Sylvester Comprehensive Cancer Ctr, Miami, FL; Univ of Alabama Comprehensive Cancer Ctr, Birmingham, AL; Univ of Wisconsin Comprehensive Cancer Ctr, Madison, WI
| | - R. J. Belt
- Winship Cancer Institute, Emory Univ, Atlanta, GA; MD Anderson Cancer Ctr, Houston, TX; MA Gen Hosp, Boston, MA; Cedars-Sinai Comprehensive Cancer Ctr, Los Angeles, CA; Kansas City Oncology Hematology Group, Kansas City, MO; Vanderbilt Univ Clin Trials Ctr, Nashville, TN; Washington Univ at St. Louis, St Louis, MO; Sylvester Comprehensive Cancer Ctr, Miami, FL; Univ of Alabama Comprehensive Cancer Ctr, Birmingham, AL; Univ of Wisconsin Comprehensive Cancer Ctr, Madison, WI
| | - D. P. Carbone
- Winship Cancer Institute, Emory Univ, Atlanta, GA; MD Anderson Cancer Ctr, Houston, TX; MA Gen Hosp, Boston, MA; Cedars-Sinai Comprehensive Cancer Ctr, Los Angeles, CA; Kansas City Oncology Hematology Group, Kansas City, MO; Vanderbilt Univ Clin Trials Ctr, Nashville, TN; Washington Univ at St. Louis, St Louis, MO; Sylvester Comprehensive Cancer Ctr, Miami, FL; Univ of Alabama Comprehensive Cancer Ctr, Birmingham, AL; Univ of Wisconsin Comprehensive Cancer Ctr, Madison, WI
| | - R. Govindan
- Winship Cancer Institute, Emory Univ, Atlanta, GA; MD Anderson Cancer Ctr, Houston, TX; MA Gen Hosp, Boston, MA; Cedars-Sinai Comprehensive Cancer Ctr, Los Angeles, CA; Kansas City Oncology Hematology Group, Kansas City, MO; Vanderbilt Univ Clin Trials Ctr, Nashville, TN; Washington Univ at St. Louis, St Louis, MO; Sylvester Comprehensive Cancer Ctr, Miami, FL; Univ of Alabama Comprehensive Cancer Ctr, Birmingham, AL; Univ of Wisconsin Comprehensive Cancer Ctr, Madison, WI
| | - L. Raez
- Winship Cancer Institute, Emory Univ, Atlanta, GA; MD Anderson Cancer Ctr, Houston, TX; MA Gen Hosp, Boston, MA; Cedars-Sinai Comprehensive Cancer Ctr, Los Angeles, CA; Kansas City Oncology Hematology Group, Kansas City, MO; Vanderbilt Univ Clin Trials Ctr, Nashville, TN; Washington Univ at St. Louis, St Louis, MO; Sylvester Comprehensive Cancer Ctr, Miami, FL; Univ of Alabama Comprehensive Cancer Ctr, Birmingham, AL; Univ of Wisconsin Comprehensive Cancer Ctr, Madison, WI
| | - F. Robert
- Winship Cancer Institute, Emory Univ, Atlanta, GA; MD Anderson Cancer Ctr, Houston, TX; MA Gen Hosp, Boston, MA; Cedars-Sinai Comprehensive Cancer Ctr, Los Angeles, CA; Kansas City Oncology Hematology Group, Kansas City, MO; Vanderbilt Univ Clin Trials Ctr, Nashville, TN; Washington Univ at St. Louis, St Louis, MO; Sylvester Comprehensive Cancer Ctr, Miami, FL; Univ of Alabama Comprehensive Cancer Ctr, Birmingham, AL; Univ of Wisconsin Comprehensive Cancer Ctr, Madison, WI
| | - J. Schiller
- Winship Cancer Institute, Emory Univ, Atlanta, GA; MD Anderson Cancer Ctr, Houston, TX; MA Gen Hosp, Boston, MA; Cedars-Sinai Comprehensive Cancer Ctr, Los Angeles, CA; Kansas City Oncology Hematology Group, Kansas City, MO; Vanderbilt Univ Clin Trials Ctr, Nashville, TN; Washington Univ at St. Louis, St Louis, MO; Sylvester Comprehensive Cancer Ctr, Miami, FL; Univ of Alabama Comprehensive Cancer Ctr, Birmingham, AL; Univ of Wisconsin Comprehensive Cancer Ctr, Madison, WI
| |
Collapse
|
33
|
Schiller JH, Fidias P, Dakhil SR, Lyss AP, Figueroa JA, Choksi JK, Loesch DM, Bloss LP, Ye Z, Obasaju CK. A phase III study of induction therapy with gemcitabine + carboplatin (GC) followed by either delayed vs. immediate second-line therapy with docetaxel (D) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7142] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. H. Schiller
- Univ of Wisconsin, Madison, WI; MA Gen Hosp, Boston, MA; Cancer Ctr of Kansas, PA, Wichita, KS; Missouri Baptist Cancer Ctr, St. Louis, MO; Joe Arrington’s Cancer Ctr, Lubbock, TX; Alamance Cancer Ctr, Burlington, NC; Central Indiana Cancer Centers, Indianapolis, IN; Eli Lilly & Co, Indianapolis, IN
| | - P. Fidias
- Univ of Wisconsin, Madison, WI; MA Gen Hosp, Boston, MA; Cancer Ctr of Kansas, PA, Wichita, KS; Missouri Baptist Cancer Ctr, St. Louis, MO; Joe Arrington’s Cancer Ctr, Lubbock, TX; Alamance Cancer Ctr, Burlington, NC; Central Indiana Cancer Centers, Indianapolis, IN; Eli Lilly & Co, Indianapolis, IN
| | - S. R. Dakhil
- Univ of Wisconsin, Madison, WI; MA Gen Hosp, Boston, MA; Cancer Ctr of Kansas, PA, Wichita, KS; Missouri Baptist Cancer Ctr, St. Louis, MO; Joe Arrington’s Cancer Ctr, Lubbock, TX; Alamance Cancer Ctr, Burlington, NC; Central Indiana Cancer Centers, Indianapolis, IN; Eli Lilly & Co, Indianapolis, IN
| | - A. P. Lyss
- Univ of Wisconsin, Madison, WI; MA Gen Hosp, Boston, MA; Cancer Ctr of Kansas, PA, Wichita, KS; Missouri Baptist Cancer Ctr, St. Louis, MO; Joe Arrington’s Cancer Ctr, Lubbock, TX; Alamance Cancer Ctr, Burlington, NC; Central Indiana Cancer Centers, Indianapolis, IN; Eli Lilly & Co, Indianapolis, IN
| | - J. A. Figueroa
- Univ of Wisconsin, Madison, WI; MA Gen Hosp, Boston, MA; Cancer Ctr of Kansas, PA, Wichita, KS; Missouri Baptist Cancer Ctr, St. Louis, MO; Joe Arrington’s Cancer Ctr, Lubbock, TX; Alamance Cancer Ctr, Burlington, NC; Central Indiana Cancer Centers, Indianapolis, IN; Eli Lilly & Co, Indianapolis, IN
| | - J. K. Choksi
- Univ of Wisconsin, Madison, WI; MA Gen Hosp, Boston, MA; Cancer Ctr of Kansas, PA, Wichita, KS; Missouri Baptist Cancer Ctr, St. Louis, MO; Joe Arrington’s Cancer Ctr, Lubbock, TX; Alamance Cancer Ctr, Burlington, NC; Central Indiana Cancer Centers, Indianapolis, IN; Eli Lilly & Co, Indianapolis, IN
| | - D. M. Loesch
- Univ of Wisconsin, Madison, WI; MA Gen Hosp, Boston, MA; Cancer Ctr of Kansas, PA, Wichita, KS; Missouri Baptist Cancer Ctr, St. Louis, MO; Joe Arrington’s Cancer Ctr, Lubbock, TX; Alamance Cancer Ctr, Burlington, NC; Central Indiana Cancer Centers, Indianapolis, IN; Eli Lilly & Co, Indianapolis, IN
| | - L. P. Bloss
- Univ of Wisconsin, Madison, WI; MA Gen Hosp, Boston, MA; Cancer Ctr of Kansas, PA, Wichita, KS; Missouri Baptist Cancer Ctr, St. Louis, MO; Joe Arrington’s Cancer Ctr, Lubbock, TX; Alamance Cancer Ctr, Burlington, NC; Central Indiana Cancer Centers, Indianapolis, IN; Eli Lilly & Co, Indianapolis, IN
| | - Z. Ye
- Univ of Wisconsin, Madison, WI; MA Gen Hosp, Boston, MA; Cancer Ctr of Kansas, PA, Wichita, KS; Missouri Baptist Cancer Ctr, St. Louis, MO; Joe Arrington’s Cancer Ctr, Lubbock, TX; Alamance Cancer Ctr, Burlington, NC; Central Indiana Cancer Centers, Indianapolis, IN; Eli Lilly & Co, Indianapolis, IN
| | - C. K. Obasaju
- Univ of Wisconsin, Madison, WI; MA Gen Hosp, Boston, MA; Cancer Ctr of Kansas, PA, Wichita, KS; Missouri Baptist Cancer Ctr, St. Louis, MO; Joe Arrington’s Cancer Ctr, Lubbock, TX; Alamance Cancer Ctr, Burlington, NC; Central Indiana Cancer Centers, Indianapolis, IN; Eli Lilly & Co, Indianapolis, IN
| |
Collapse
|
34
|
Sequist LV, Fidias P, Temel J, Kennedy BA, Ostler PA, Rabin MS, Huberman M, Keck J, Brown GL, Lynch TJ. Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7275] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. V. Sequist
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Telik, Inc., Palo Alto, CA
| | - P. Fidias
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Telik, Inc., Palo Alto, CA
| | - J. Temel
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Telik, Inc., Palo Alto, CA
| | - B. A. Kennedy
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Telik, Inc., Palo Alto, CA
| | - P. A. Ostler
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Telik, Inc., Palo Alto, CA
| | - M. S. Rabin
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Telik, Inc., Palo Alto, CA
| | - M. Huberman
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Telik, Inc., Palo Alto, CA
| | - J. Keck
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Telik, Inc., Palo Alto, CA
| | - G. L. Brown
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Telik, Inc., Palo Alto, CA
| | - T. J. Lynch
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Telik, Inc., Palo Alto, CA
| |
Collapse
|
35
|
Fidias P, Pirl W, Temel J, Cashavelly B, Lynch TJ. Screening for cancer-related fatigue (CRF) in a thoracic oncology clinic is feasible. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Bloss LP, Ye Z, Obasaju C, Kindler HL. An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. A. Janne
- Dana-Farber Cancer Inst, Boston, MA; H. Lee Moffitt Cancer Ctr, Tampa, FL; Fox Chase Cancer Ctr, Philadelphia, PA; Columbia Coll of Physicians and Surgeons, New York, NY; Case Western Reserve Univ, Cleveland, OH; MA Gen Hosp, Boston, MA; Eli Lilly & Co, Indianapolis, IN; The Univ of Chicago, Chicago, IL
| | - G. R. Simon
- Dana-Farber Cancer Inst, Boston, MA; H. Lee Moffitt Cancer Ctr, Tampa, FL; Fox Chase Cancer Ctr, Philadelphia, PA; Columbia Coll of Physicians and Surgeons, New York, NY; Case Western Reserve Univ, Cleveland, OH; MA Gen Hosp, Boston, MA; Eli Lilly & Co, Indianapolis, IN; The Univ of Chicago, Chicago, IL
| | - C. J. Langer
- Dana-Farber Cancer Inst, Boston, MA; H. Lee Moffitt Cancer Ctr, Tampa, FL; Fox Chase Cancer Ctr, Philadelphia, PA; Columbia Coll of Physicians and Surgeons, New York, NY; Case Western Reserve Univ, Cleveland, OH; MA Gen Hosp, Boston, MA; Eli Lilly & Co, Indianapolis, IN; The Univ of Chicago, Chicago, IL
| | - R. N. Taub
- Dana-Farber Cancer Inst, Boston, MA; H. Lee Moffitt Cancer Ctr, Tampa, FL; Fox Chase Cancer Ctr, Philadelphia, PA; Columbia Coll of Physicians and Surgeons, New York, NY; Case Western Reserve Univ, Cleveland, OH; MA Gen Hosp, Boston, MA; Eli Lilly & Co, Indianapolis, IN; The Univ of Chicago, Chicago, IL
| | - A. Dowlati
- Dana-Farber Cancer Inst, Boston, MA; H. Lee Moffitt Cancer Ctr, Tampa, FL; Fox Chase Cancer Ctr, Philadelphia, PA; Columbia Coll of Physicians and Surgeons, New York, NY; Case Western Reserve Univ, Cleveland, OH; MA Gen Hosp, Boston, MA; Eli Lilly & Co, Indianapolis, IN; The Univ of Chicago, Chicago, IL
| | - P. Fidias
- Dana-Farber Cancer Inst, Boston, MA; H. Lee Moffitt Cancer Ctr, Tampa, FL; Fox Chase Cancer Ctr, Philadelphia, PA; Columbia Coll of Physicians and Surgeons, New York, NY; Case Western Reserve Univ, Cleveland, OH; MA Gen Hosp, Boston, MA; Eli Lilly & Co, Indianapolis, IN; The Univ of Chicago, Chicago, IL
| | - L. P. Bloss
- Dana-Farber Cancer Inst, Boston, MA; H. Lee Moffitt Cancer Ctr, Tampa, FL; Fox Chase Cancer Ctr, Philadelphia, PA; Columbia Coll of Physicians and Surgeons, New York, NY; Case Western Reserve Univ, Cleveland, OH; MA Gen Hosp, Boston, MA; Eli Lilly & Co, Indianapolis, IN; The Univ of Chicago, Chicago, IL
| | - Z. Ye
- Dana-Farber Cancer Inst, Boston, MA; H. Lee Moffitt Cancer Ctr, Tampa, FL; Fox Chase Cancer Ctr, Philadelphia, PA; Columbia Coll of Physicians and Surgeons, New York, NY; Case Western Reserve Univ, Cleveland, OH; MA Gen Hosp, Boston, MA; Eli Lilly & Co, Indianapolis, IN; The Univ of Chicago, Chicago, IL
| | - C. Obasaju
- Dana-Farber Cancer Inst, Boston, MA; H. Lee Moffitt Cancer Ctr, Tampa, FL; Fox Chase Cancer Ctr, Philadelphia, PA; Columbia Coll of Physicians and Surgeons, New York, NY; Case Western Reserve Univ, Cleveland, OH; MA Gen Hosp, Boston, MA; Eli Lilly & Co, Indianapolis, IN; The Univ of Chicago, Chicago, IL
| | - H. L. Kindler
- Dana-Farber Cancer Inst, Boston, MA; H. Lee Moffitt Cancer Ctr, Tampa, FL; Fox Chase Cancer Ctr, Philadelphia, PA; Columbia Coll of Physicians and Surgeons, New York, NY; Case Western Reserve Univ, Cleveland, OH; MA Gen Hosp, Boston, MA; Eli Lilly & Co, Indianapolis, IN; The Univ of Chicago, Chicago, IL
| |
Collapse
|
37
|
Jackman D, Lucca J, Fidias P, Rabin MS, Lynch TJ, Ostler P, Skarin AT, Temel J, Johnson BE, Janne PA. Phase II study of the EGFR tyrosine kinase erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7148] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Jackman
- Dana-Farber Cancer Inst, Boston, MA; MA Gen Hosp, Boston, MA
| | - J. Lucca
- Dana-Farber Cancer Inst, Boston, MA; MA Gen Hosp, Boston, MA
| | - P. Fidias
- Dana-Farber Cancer Inst, Boston, MA; MA Gen Hosp, Boston, MA
| | - M. S. Rabin
- Dana-Farber Cancer Inst, Boston, MA; MA Gen Hosp, Boston, MA
| | - T. J. Lynch
- Dana-Farber Cancer Inst, Boston, MA; MA Gen Hosp, Boston, MA
| | - P. Ostler
- Dana-Farber Cancer Inst, Boston, MA; MA Gen Hosp, Boston, MA
| | - A. T. Skarin
- Dana-Farber Cancer Inst, Boston, MA; MA Gen Hosp, Boston, MA
| | - J. Temel
- Dana-Farber Cancer Inst, Boston, MA; MA Gen Hosp, Boston, MA
| | - B. E. Johnson
- Dana-Farber Cancer Inst, Boston, MA; MA Gen Hosp, Boston, MA
| | - P. A. Janne
- Dana-Farber Cancer Inst, Boston, MA; MA Gen Hosp, Boston, MA
| |
Collapse
|
38
|
Ryan DP, Eder JP, Appleman L, Fidias P, Johnson B, Lucca J, Aluri J, Owa T, Renshaw FG, Shapiro G. A phase I study of E7070, a chloroindolyl-sulfonamide, in combination with irinotecan in gastrointestinal and thoracic carcinomas. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2031] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. P. Ryan
- Dana-Farber Cancer Inst, Boston, MA; Eisai Medcl Research, Ridgefield Park, NJ; Eisai Tsukabu, Tokoyo, Japan
| | - J. P. Eder
- Dana-Farber Cancer Inst, Boston, MA; Eisai Medcl Research, Ridgefield Park, NJ; Eisai Tsukabu, Tokoyo, Japan
| | - L. Appleman
- Dana-Farber Cancer Inst, Boston, MA; Eisai Medcl Research, Ridgefield Park, NJ; Eisai Tsukabu, Tokoyo, Japan
| | - P. Fidias
- Dana-Farber Cancer Inst, Boston, MA; Eisai Medcl Research, Ridgefield Park, NJ; Eisai Tsukabu, Tokoyo, Japan
| | - B. Johnson
- Dana-Farber Cancer Inst, Boston, MA; Eisai Medcl Research, Ridgefield Park, NJ; Eisai Tsukabu, Tokoyo, Japan
| | - J. Lucca
- Dana-Farber Cancer Inst, Boston, MA; Eisai Medcl Research, Ridgefield Park, NJ; Eisai Tsukabu, Tokoyo, Japan
| | - J. Aluri
- Dana-Farber Cancer Inst, Boston, MA; Eisai Medcl Research, Ridgefield Park, NJ; Eisai Tsukabu, Tokoyo, Japan
| | - T. Owa
- Dana-Farber Cancer Inst, Boston, MA; Eisai Medcl Research, Ridgefield Park, NJ; Eisai Tsukabu, Tokoyo, Japan
| | - F. G. Renshaw
- Dana-Farber Cancer Inst, Boston, MA; Eisai Medcl Research, Ridgefield Park, NJ; Eisai Tsukabu, Tokoyo, Japan
| | - G. Shapiro
- Dana-Farber Cancer Inst, Boston, MA; Eisai Medcl Research, Ridgefield Park, NJ; Eisai Tsukabu, Tokoyo, Japan
| |
Collapse
|
39
|
Heymach JV, Dong RP, Dimery I, Wheeler C, Fidias P, Lu C, Johnson B, Herbst R. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3051] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. V. Heymach
- Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - R.-P. Dong
- Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - I. Dimery
- Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - C. Wheeler
- Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - P. Fidias
- Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - C. Lu
- Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - B. Johnson
- Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - R. Herbst
- Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
40
|
Roof KS, Coen J, Lynch TJ, Wright CD, Fidias P, Willett CG, Choi NC. Neo-adjuvant radiation, cisplatin, 5-FU +/− paclitaxel in locally advanced esophageal cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. S. Roof
- Massachusetts General Hospital, Boston, MA
| | - J. Coen
- Massachusetts General Hospital, Boston, MA
| | | | | | - P. Fidias
- Massachusetts General Hospital, Boston, MA
| | | | - N. C. Choi
- Massachusetts General Hospital, Boston, MA
| |
Collapse
|
41
|
Janne PA, Obasaju C, Simon G, Taub R, Kelly K, Fidias P, Bloss LP, Kindler HL. A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. A. Janne
- Dana Farber Cancer Institute, Boston, MA; Lilly Oncology, Indianapolis, IN; H. Lee Moffitt Cancer Center, Tampa, FL; Columbia University College, New York, NY; University of Colorado Health Sciences Center, Denver, CO; Massachusetts General Hospital, Boston, MA; University of Chicago Medical Center, Chicago, IL
| | - C. Obasaju
- Dana Farber Cancer Institute, Boston, MA; Lilly Oncology, Indianapolis, IN; H. Lee Moffitt Cancer Center, Tampa, FL; Columbia University College, New York, NY; University of Colorado Health Sciences Center, Denver, CO; Massachusetts General Hospital, Boston, MA; University of Chicago Medical Center, Chicago, IL
| | - G. Simon
- Dana Farber Cancer Institute, Boston, MA; Lilly Oncology, Indianapolis, IN; H. Lee Moffitt Cancer Center, Tampa, FL; Columbia University College, New York, NY; University of Colorado Health Sciences Center, Denver, CO; Massachusetts General Hospital, Boston, MA; University of Chicago Medical Center, Chicago, IL
| | - R. Taub
- Dana Farber Cancer Institute, Boston, MA; Lilly Oncology, Indianapolis, IN; H. Lee Moffitt Cancer Center, Tampa, FL; Columbia University College, New York, NY; University of Colorado Health Sciences Center, Denver, CO; Massachusetts General Hospital, Boston, MA; University of Chicago Medical Center, Chicago, IL
| | - K. Kelly
- Dana Farber Cancer Institute, Boston, MA; Lilly Oncology, Indianapolis, IN; H. Lee Moffitt Cancer Center, Tampa, FL; Columbia University College, New York, NY; University of Colorado Health Sciences Center, Denver, CO; Massachusetts General Hospital, Boston, MA; University of Chicago Medical Center, Chicago, IL
| | - P. Fidias
- Dana Farber Cancer Institute, Boston, MA; Lilly Oncology, Indianapolis, IN; H. Lee Moffitt Cancer Center, Tampa, FL; Columbia University College, New York, NY; University of Colorado Health Sciences Center, Denver, CO; Massachusetts General Hospital, Boston, MA; University of Chicago Medical Center, Chicago, IL
| | - L. P. Bloss
- Dana Farber Cancer Institute, Boston, MA; Lilly Oncology, Indianapolis, IN; H. Lee Moffitt Cancer Center, Tampa, FL; Columbia University College, New York, NY; University of Colorado Health Sciences Center, Denver, CO; Massachusetts General Hospital, Boston, MA; University of Chicago Medical Center, Chicago, IL
| | - H. L. Kindler
- Dana Farber Cancer Institute, Boston, MA; Lilly Oncology, Indianapolis, IN; H. Lee Moffitt Cancer Center, Tampa, FL; Columbia University College, New York, NY; University of Colorado Health Sciences Center, Denver, CO; Massachusetts General Hospital, Boston, MA; University of Chicago Medical Center, Chicago, IL
| |
Collapse
|
42
|
Fanucchi MP, Belt RJ, Fossella FV, Natale RB, Robert F, Fidias P, Kelly K, Kashala O, Schenkein DP, Schiller JH. Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7107] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. P. Fanucchi
- Emory University Winship Cancer Institute, Atlanta, GA; Kansa City Cancer Centers, Kansas City, MO; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Alabama of Birmingham, Birmingham, AL; Massachusetts General Hospital, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Millennium Pharmaceuticals, Cambridge, MA; Millennium Pharmaceuticals, Inc., Cambridge, MA; University of Wisconsin Hospital & Clinics, Madison, WI
| | - R. J. Belt
- Emory University Winship Cancer Institute, Atlanta, GA; Kansa City Cancer Centers, Kansas City, MO; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Alabama of Birmingham, Birmingham, AL; Massachusetts General Hospital, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Millennium Pharmaceuticals, Cambridge, MA; Millennium Pharmaceuticals, Inc., Cambridge, MA; University of Wisconsin Hospital & Clinics, Madison, WI
| | - F. V. Fossella
- Emory University Winship Cancer Institute, Atlanta, GA; Kansa City Cancer Centers, Kansas City, MO; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Alabama of Birmingham, Birmingham, AL; Massachusetts General Hospital, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Millennium Pharmaceuticals, Cambridge, MA; Millennium Pharmaceuticals, Inc., Cambridge, MA; University of Wisconsin Hospital & Clinics, Madison, WI
| | - R. B. Natale
- Emory University Winship Cancer Institute, Atlanta, GA; Kansa City Cancer Centers, Kansas City, MO; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Alabama of Birmingham, Birmingham, AL; Massachusetts General Hospital, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Millennium Pharmaceuticals, Cambridge, MA; Millennium Pharmaceuticals, Inc., Cambridge, MA; University of Wisconsin Hospital & Clinics, Madison, WI
| | - F. Robert
- Emory University Winship Cancer Institute, Atlanta, GA; Kansa City Cancer Centers, Kansas City, MO; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Alabama of Birmingham, Birmingham, AL; Massachusetts General Hospital, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Millennium Pharmaceuticals, Cambridge, MA; Millennium Pharmaceuticals, Inc., Cambridge, MA; University of Wisconsin Hospital & Clinics, Madison, WI
| | - P. Fidias
- Emory University Winship Cancer Institute, Atlanta, GA; Kansa City Cancer Centers, Kansas City, MO; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Alabama of Birmingham, Birmingham, AL; Massachusetts General Hospital, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Millennium Pharmaceuticals, Cambridge, MA; Millennium Pharmaceuticals, Inc., Cambridge, MA; University of Wisconsin Hospital & Clinics, Madison, WI
| | - K. Kelly
- Emory University Winship Cancer Institute, Atlanta, GA; Kansa City Cancer Centers, Kansas City, MO; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Alabama of Birmingham, Birmingham, AL; Massachusetts General Hospital, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Millennium Pharmaceuticals, Cambridge, MA; Millennium Pharmaceuticals, Inc., Cambridge, MA; University of Wisconsin Hospital & Clinics, Madison, WI
| | - O. Kashala
- Emory University Winship Cancer Institute, Atlanta, GA; Kansa City Cancer Centers, Kansas City, MO; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Alabama of Birmingham, Birmingham, AL; Massachusetts General Hospital, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Millennium Pharmaceuticals, Cambridge, MA; Millennium Pharmaceuticals, Inc., Cambridge, MA; University of Wisconsin Hospital & Clinics, Madison, WI
| | - D. P. Schenkein
- Emory University Winship Cancer Institute, Atlanta, GA; Kansa City Cancer Centers, Kansas City, MO; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Alabama of Birmingham, Birmingham, AL; Massachusetts General Hospital, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Millennium Pharmaceuticals, Cambridge, MA; Millennium Pharmaceuticals, Inc., Cambridge, MA; University of Wisconsin Hospital & Clinics, Madison, WI
| | - J. H. Schiller
- Emory University Winship Cancer Institute, Atlanta, GA; Kansa City Cancer Centers, Kansas City, MO; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Alabama of Birmingham, Birmingham, AL; Massachusetts General Hospital, Boston, MA; University of Colorado Health Sciences Center, Denver, CO; Millennium Pharmaceuticals, Cambridge, MA; Millennium Pharmaceuticals, Inc., Cambridge, MA; University of Wisconsin Hospital & Clinics, Madison, WI
| |
Collapse
|
43
|
Enzinger PC, Clark J, Ryan D, Meyerhardt J, Kulke M, Fidias P, Earle C, Vincitore M, Michelini A, Fuchs C. Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - J. Clark
- Dana Farber/Partners Cancer Care (DFPCC), Boston, MA
| | - D. Ryan
- Dana Farber/Partners Cancer Care (DFPCC), Boston, MA
| | - J. Meyerhardt
- Dana Farber/Partners Cancer Care (DFPCC), Boston, MA
| | - M. Kulke
- Dana Farber/Partners Cancer Care (DFPCC), Boston, MA
| | - P. Fidias
- Dana Farber/Partners Cancer Care (DFPCC), Boston, MA
| | - C. Earle
- Dana Farber/Partners Cancer Care (DFPCC), Boston, MA
| | - M. Vincitore
- Dana Farber/Partners Cancer Care (DFPCC), Boston, MA
| | - A. Michelini
- Dana Farber/Partners Cancer Care (DFPCC), Boston, MA
| | - C. Fuchs
- Dana Farber/Partners Cancer Care (DFPCC), Boston, MA
| |
Collapse
|
44
|
Park S, Choi N, Wright C, Lynch T, Ancukiewicz M, Wain J, Donahue D, Fidias P, Mathisen D. Twice daily radiation as concomitant boost during two cycles of Cisplatin (C), 5-Fu (F) and Taxol (T) in preoperative chemo-radiotherapy (CT-RT) for esophageal cancer: mature results of phase I/II study. Int J Radiat Oncol Biol Phys 2002. [DOI: 10.1016/s0360-3016(02)03283-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
45
|
Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001; 7:3942-9. [PMID: 11751486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
PURPOSE Our aim was to evaluate the efficacy, toxicity, and pharmacokinetic behavior of single-agent paclitaxel given weekly to elderly patients with lung cancer. EXPERIMENTAL DESIGN Previously untreated patients with stage IIIB/IV non-small cell lung cancer were eligible for the study if they were at least 70 years of age and had preserved organ function. Paclitaxel was administered over 1 h at a dose of 90 mg/m(2) for 6 consecutive weeks on an 8-week cycle. The pharmacokinetics of paclitaxel were assessed during the first and sixth week of therapy in a subgroup of eight patients. RESULTS A total of 35 patients (median age, 76 years; range, 70-85) were enrolled. The overall response rate was 23%. Median time to failure was 5.2 months, whereas the median survival time was 10.3 months. Survival rates after 1 and 2 years were 45 and 22%, respectively. Grade 3/4 toxicities included neutropenia (5.8%), hyperglycemia (17.6%), neuropathy (5.8%), and infection (8.8%). Two patients died from treatment-related toxicity. There was no significant difference (P = 0.18) between the total body clearance of paclitaxel on the first (17.4 +/- 2.9 liters/h/m(2), mean +/- SD) and sixth (15.8 +/- 4.1 liters/h/m(2)) week of therapy. CONCLUSION Paclitaxel administered as a weekly 1-h infusion at a dose of 90 mg/m(2) is a safe and effective therapy for elderly patients with advanced non-small cell lung cancer. Its pharmacokinetics in elderly patients do not appear to differ from historical data for younger patients, and there was no suggestion of a change in drug clearance after repeated weekly dosing.
Collapse
Affiliation(s)
- P Fidias
- Division of Hematology-Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 201, Boston, MA 02114, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Fidias P, Supko J, Martins R, Boral A, Skarin A, Johnson B, Carey R, Grossbard M, Vasconcelles M, Shapiro G, Lynch T. A phase II clinical and pharmacokinetic study of weekly paclitaxel in elderly patients with non-small cell lung cancer. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80184-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Fidias P, Spiro I, Sobczak ML, Nielsen GP, Ruffolo EF, Mankin H, Suit HD, Harmon DC. Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys 1999; 45:1213-8. [PMID: 10613315 DOI: 10.1016/s0360-3016(99)00305-3] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE To report the Massachusetts General Hospital experience in the management of patients with primary bone lymphoma (PBL) treated with combined modality therapy (CMT). METHODS AND MATERIALS Records from 37 eligible patients were reviewed. Two patients were treated with complete resection of the tumor, while 35 patients underwent radiation therapy with a median total dose of 54 Gy (range 38.35-66.5). All patients received combination chemotherapy, which contained doxorubicin in 33 cases. We compared the current data with our previous experience in patients treated with local measures only. RESULTS Actuarial disease-free survival (DFS) at 5 and 10 years is 78% and 73%, respectively, while overall survival (OS) is 91% and 87%, respectively. No local failures were seen. Pathologic fracture at presentation influenced DFS (p = 0.005) and OS (p = 0.017) adversely. OS was compromised in patients older than 60 years (p = 0.059) and DFS in patients with pelvic primaries (p = 0.015). CMT was associated with improved DFS (p = 0.0008) and OS p = 0.0001) compared to our historical controls. Ten patients (27%) developed complications requiring orthopedic procedures following completion of therapy at a median of 25.5 months (range 4-228). CONCLUSION Patients with PBL have a favorable outcome with CMT, which appears superior to radiation therapy alone. Late complications can be seen, especially in weight-bearing bones.
Collapse
Affiliation(s)
- P Fidias
- Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Grossbard ML, Fidias P, Kinsella J, O'Toole J, Lambert JM, Blattler WA, Esseltine D, Braman G, Nadler LM, Anderson KC. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. Br J Haematol 1998; 102:509-15. [PMID: 9695966 DOI: 10.1046/j.1365-2141.1998.00799.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
This phase II trial was undertaken to determine the toxicities, response rate, pharmacokinetics and frequency of human anti-mouse antibody (HAMA) and anti-ricin antibody (HARA) when the B-cell restricted immunotoxin anti-B4-bR was administered to patients with previously treated multiple myeloma (MM). Five patients with MM were scheduled to receive a 7 d continuous infusion of anti-B4-bR. The initial four patients received therapy at 40 microg/kg lean body weight (LBW)/d. Two patients received a 7 d infusion, one patient received 6 d, and another patient 5 d of therapy. The fifth patient was treated for 7 d at a lower dose of 30 microg/kg LBW/d because of the side-effects observed in the initial patients. Pharmacokinetic studies demonstrated a peak serum level >2.6 nM in three of the patients. Side-effects of therapy included hepatic transaminase elevations, myalgias, thrombocytopenia, nausea, vomiting, decrease in performance status, and capillary leak syndrome. One patient developed HAMA and two patients HARA. One patient developed neurologic toxicity with akinetic mutism, and died following therapy. No patient demonstrated a significant decline in M-component during therapy. We concluded that anti-B4-bR can be administered by continuous infusion to patients with multiple myeloma, although immunotoxin levels >3 nM were associated with increased incidence of toxicity and required dose adjustment. Future trials using anti-B4-bR in MM will be needed to determine the optimal dose and administration schedule in this patient population, and to determine whether there is evidence of biologic activity.
Collapse
Affiliation(s)
- M L Grossbard
- Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Johnston PG, Takimoto CH, Grem JL, Fidias P, Grossbard ML, Chabner BA, Allegra CJ, Chu E. Antimetabolites. Cancer Chemother Biol Response Modif 1998; 17:1-39. [PMID: 9551206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- P G Johnston
- Department of Oncology, Queens University of Belfast City Hospital, Northern Ireland
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Fidias P, Fan CM, McGovern FJ, Wright CD, Kaufman J, Grossbard ML. Intracaval extension of germ cell carcinoma: diagnosis via endovascular biopsy and a review of the literature. Eur Urol 1997; 31:376-9. [PMID: 9129935 DOI: 10.1159/000474487] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We report a case of testicular carcinoma invading the inferior vena cava. Tumor invasion was diagnosed via endovascular biopsy. This is the first known report of a diagnosis of this entity using endovascular biopsy. We also review the literature on diagnosis and management of inferior vena caval involvement by testicular cancer.
Collapse
Affiliation(s)
- P Fidias
- Hematology-Oncology Unit, Massachusetts General Hospital, Boston 02114, USA
| | | | | | | | | | | |
Collapse
|